Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasinumab for Peripheral Nerve Function in OA Pain
NCT03691974Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in osteoarthritis (OA) comparing Fasinumab with Placebo (2 arms). Primary endpoints: Change From Baseline in Peroneal Motor Nerve Conduction Velocity at 16 weeks, Change From Baseline in Peroneal Motor Nerve Action Potential Amplitude at 16 weeks and 4 more. Started Oct 2018; status: completed.
02
Drugs
fasinumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03691974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691974.